[Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab) in pre-exposure prophylaxis in humans].
BACKGROUND
A WHO experts committee recommended the substitution of antirabic vaccines produced in nervous tissue, by vaccines produced in tissue cultures.


OBJECTIVE
To compare the immunogenic capacity of antirabic vaccines CRL (produced in nervous tissue) and Verorab (produced in tissue culture), used for pre-exposure prophylaxis in humans.


METHODS
Fifty four volunteers were immunized for this study. The first group, vaccinated with CLR was treated with a scheme of 4 subcutaneous peri umbilical doses in days 0, 3, 7 and 28. The second group, vaccinated with Verorab vaccine was treated with a scheme of 3 intramuscular doses in deltoid zone at days 0, 7 and 28. Blood samples were obtained at days 0, 7, 42 and 365 to measure neutralizing antibodies using the Inhibition of Fluorescent Focus Technique (RFFIT).


RESULTS
At day seven, a primary non protective immunologic response was observed in both groups, with titers significantly higher in the group vaccinated with Verorab. At day 42, no differences were observed. At day 365, all subjects vaccinated with Verorab and 50% of individuals vaccinated with CRL had protective antibody titers (p <0.05).


CONCLUSIONS
The vaccine produced in cell breeds (Verorab) produces a better an faster immunologic response compared to the CRL vaccine.
Favi
Myriam
M
Médico Veterinario, Instituto de Salud Pública de Chile, Santiago. mfavi@ispch.cl
Yung
Verónica
V
Roos
Orietta
O
Rodríguez
Luis
L
Trujillo
Rodrigo
R
Acevedo
Attia
A
D000328:Adult; D000818:Animals; D000833:Animals, Suckling; D000914:Antibodies, Viral / Q000302:isolation & purification; D001921:Brain / Q000276:immunology / Q000821:virology; D002522:Chlorocebus aethiops; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D009417:Nerve Tissue; D011819:Rabies Vaccines / Q000276:immunology*; D046509:Tissue Culture Techniques; D014709:Vero Cells
D000914:Antibodies, Viral; D011819:Rabies Vaccines
Evaluación de la capacidad inmunogénica de la vacuna antirrábica tipo Fuenzalida- Palacios (CRL) y de la vacuna antirrábica de cultivo celular (Verorab) en personas con tratamiento preexposición.